Prognostic value of stem cell markers in glioblastoma

Francesc Alameda, José María Velarde, Cristina Carrato, Noemí Vidal, Montserrat Arumí, Dolores Naranjo, Maria Martinez-Garcia, Teresa Ribalta, Carme Balañá

Producción científica: Contribución a una revistaArtículoInvestigación

5 Citas (Scopus)


© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Background/Context: Glioblastoma (GB) is the most common primary brain tumour in adults and it is associated with a high mortality rate. According to the stem cell theory, the growth, relapse and treatment response of GB is determined by the stem cell subpopulation present in the tumour. Objective: Our aim is to study the prognostic value of stem cell markers (CD44, Nestin, Olig2 and SOX2) in a series of homogeneously treated GBs. Material and methods: We study 280 GBs treated with STUPP acheme with a histologican review of the cases and TMA with a máximum of 4 spots for each case. Each slide was immunohistochemically stained and Reading. We compared the immunohistochemical results with survival tme. Results: Only SOX2 immunoexpression (IE) excedding 10% of the tumour cells was found to be related to good survival (p= 0.037) in univariate analysis. However, amultivariate analysis indicate the age, surgery and MGMT promotes methylation but no SOX2 IE are prognostic factors. Conclusions: We conclude the immunohistochemical studies of stem cell markers in GB are not useful for predicting prognosis in daily practice.
Idioma originalInglés
Páginas (desde-hasta)677-683
EstadoPublicada - 3 oct 2019


Profundice en los temas de investigación de 'Prognostic value of stem cell markers in glioblastoma'. En conjunto forman una huella única.

Citar esto